# Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

> **NCT00224068** · PHASE4 · COMPLETED · sponsor: **Watson Pharmaceuticals** · enrollment: 180 (—)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Sodium ferric gluconate, ferrous sulfate, standard of care

## Key facts

- **NCT ID:** NCT00224068
- **Lead sponsor:** Watson Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** 180 (—)
- **Last updated:** 2012-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00224068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00224068, "Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00224068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*